Supscore leest: Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review

Supscore leest nu:

Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review

While the recreational use of cannabis has well-established dose-dependent effects on neurocognitive and psychomotor functioning, there is little consensus on the degree and duration of impairment typically seen with medical marijuana use.

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/30KAZhW

Supscore leest: A Higher Authority: Canada’s Cannabis Legalization in the Context of International Law

Supscore leest nu: A Higher Authority: Canada’s Cannabis Legalization in the Context
of International Law 

Antonia Eliason, University of Mississippi School of Law
Robert HowseNYU Law School

Abstract: Part I of this Article provides an overview of some of the key terms and provisions of Canada’s Cannabis Act. Part II looks at the Cannabis Act in the context of the International Drug Conventions, examining how the various convention provisions might apply, looking first at the Single Convention and then at the 1988 Convention and how that convention fits with Canadian constitutional provisions. Part III focuses on the international human rights framework and how the Cannabis Act might be viewed as compatible with international human rights law even where incompatible with the International Drug Conventions. This Part also offers a look at some of the cannabis-related human rights jurisprudence that arose in various jurisdictions. Finally, Part IV analyzes the Cannabis Act in light of the international economic law framework, providing an in-depth overview of how various WTO provisions might affect the Cannabis Act as drafted.

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/2O4HNoh

Supscore leest: Voluntary contribution to INCB Cannabis Guidelines – due diligence, good faith, & technical concerns

Supscore leest nu:

Voluntary contribution to INCB Cannabis Guidelines – due diligence, good faith, & technical concerns

Technical ReportPDF Available Voluntary contribution to INCB Cannabis Guidelines – due diligence, good faith, & technical concerns Authors: Download full-text PDF In March 2020, the International Narcotics Control Board (INCB) launched a “Cannabis Initiative” with the purpose of issuing “gu

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/3uSOydb

Supscore leest: Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis

Supscore leest nu:

Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis

as it appeared in Multiple Sclerosis And Related Disorders, https://doi.org/10.1016/j.msard.2020.102708

Highlights

  • Medical cannabis treatment at low dose was safe and well tolerated in MS.
  • Treatment resulted in a reduction in pain intensity, spasticity and sleep disturbances.
  • Treatment showed no impairment in ambulation, dexterity or processing speed.
  • Medical cannabis can be used as an alternative to treat spasticity and pain in MS.
  • N=28

Abstract:

Introduction

The use of cannabis as medical therapy to treat chronic pain and spasticity in patients with multiple sclerosis (MS) is increasing. However, the evidence on safety when initiating treatment with medical cannabis oils is limited. The aim of this study was to investigate the safety of sublingual medical cannabis oils in patients with MS.

Methods

In this prospective observational safety study 28 patients with MS were treated with medical cannabis oils (THC-rich, CBD-rich and THC+CBD combined products) and were followed during a titration period of four weeks. Patients were evaluated at treatment start (Visit 1) and after four weeks treatment (Visit 2). At each visit neurological examination (Expanded Disability Status Scale – EDSS), ambulation (Timed 25-Foot Walk Test – T25FWT), routine blood tests, plasma cannabinoids, dexterity (9-Hole Peg Test – 9-HPT) and processing speed (Symbol Digit Modalities Test – SDMT) were tested. Adverse events (AEs) and tolerability were reported at Visit 2. Secondary, efficacy of medical cannabis on pain, spasticity and sleep disturbances were measured by numeric rating scale (NRS-11) each day during the 4-week treatment period.

Results

During treatment with cannabis preparations containing 10-25 mg/mL THC, the most common AEs were dry mouth, drowsiness, dizziness and nausea of mild to moderate degree. Two patients experienced pronounced symptoms with excessive dreaming and drowsiness, respectively, which led to treatment stop during the titration. Three serious adverse events (SAE) were reported but were not associated with the treatment. Mean doses of THC and CBD were 4.0 mg and 7.0 mg, respectively, and primarily administered as a once-daily evening dose. Furthermore, pain decreased from a median NRS score of 7 to 4, ( p = 0.01), spasticity decreased from a median NRS score of 6 to 2.5 ( p = 0.01) and sleep disturbances decreased from a median NRS score of 7 to 3 ( p < 0.001). No impairment in disability, ambulation, dexterity or processing speed was observed.

Conclusion

Treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients. This suggests that medical cannabis oils can be used safely, especially at relatively low doses and with slow titration, as an alternative to treat MS-related symptoms when conventional therapy is inadequate.

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/2K6LpA4

Supscore leest: Carbonyl Compounds Produced by Vaporizing Cannabis Oil Thinning Agents

Supscore leest nu:

Carbonyl Compounds Produced by Vaporizing Cannabis Oil Thinning Agents

Objective: Cannabis use has increased in the United States, particularly the use of vaporized cannabis oil, which is often mixed with thinning agents for use in vaporizing devices.

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/3rf03cC

Supscore leest: How Should We Talk About Cannabis?

Supscore leest nu:

How Should We Talk About Cannabis?

“Cannabis, weed, ganja, pot…there is an almost endless list of names used to refer to the Cannabis sativa plant and its products.

But when it comes to law and policy, what are the definitive terms we should be using when talking about cannabis? Is the current lexicon used by cannabis industry insiders appropriate?

Not always, according to a new study.”

Alexander Beadle about Kenzi Riboulet-Zemouli’s work researching principal information and definitions about Cannabis. These definitions are the foundation of legal frameworks for (inter)national lawmaking.

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/2NEyhIf

Supscore leest: Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

Supscore leest nu:

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

Growing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure of administering a fixed dose.

From Journal of Psychopharmacology by Sage Publishers

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/3kkxW9n

Supscore leest: Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

Supscore leest nu:

Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

Abstract

Peripheral inflammatory conditions, including those localized to the gastrointestinal tract, are highly comorbid with psychiatric disorders such as anxiety and depression. These behavioral symptoms are poorly managed by conventional treatments for inflammatory diseases and contribute to quality of life impairments. Peripheral inflammation is associated with sustained elevations in circulating glucocorticoid hormones, which can modulate central processes, including those involved in the regulation of emotional behavior. The endocannabinoid (eCB) system is exquisitely sensitive to these hormonal changes and is a significant regulator of emotional behavior. The impact of peripheral inflammation on central eCB function, and whether this is related to the development of these behavioral comorbidities remains to be determined. To examine this, we employed the trinitrobenzene sulfonic acid-induced model of colonic inflammation (colitis) in adult, male, Sprague Dawley rats to produce sustained peripheral inflammation. Colitis produced increases in behavioral measures of anxiety and elevations in circulating corticosterone. These alterations were accompanied by elevated hydrolytic activity of the enzyme fatty acid amide hydrolase (FAAH), which hydrolyzes the eCB anandamide (AEA), throughout multiple corticolimbic brain regions. This elevation of FAAH activity was associated with broad reductions in the content of AEA, whose decline was driven by central corticotropin releasing factor type 1 receptor signaling. Colitis-induced anxiety was reversed following acute central inhibition of FAAH, suggesting that the reductions in AEA produced by colitis contributed to the generation of anxiety. These data provide a novel perspective for the pharmacological management of psychiatric comorbidities of chronic inflammatory conditions through modulation of eCB signaling.

Haley A VecchiarelliMaria MorenaCatherine M KeenanVincent ChiangKaitlyn TanMin QiaoKira LeitlAlessia SantoriQuentin J PittmanKeith A SharkeyMatthew N Hill

Dit bericht is automatisch gegenereerd. Zie de bron op Pocket
https://ift.tt/3kge7jH